Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Maruo Calcium Co., Ltd. (4102.T)
Akashi, JP
Maruo Calcium Co., Ltd., a Japan-based firm, specializes in the manufacturing and sale of diverse calcium carbonate products and various other industrial raw materials. Its comprehensive product line includes multiple forms of calcium carbonate, such as colloidal, light, ground, and food-grade types. The company also supplies animal feeds, hydrated and quick lime, wet silica products, and an assortment of minerals like talc, clay, and silica powder. Additionally, Maruo Calcium imports and distributes wet silica products. These materials are widely utilized across numerous sectors, finding application in sealants, adhesives, plastisols, films, plastics, paints, inks, rubber, and as food additives, among other uses. Founded in 1926, the company, headquartered in Akashi, Japan, was originally known as Maruo Seifun Goshi Company before changing its name to Maruo Calcium Co., Ltd. in August 1963.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | -2.53% | +1.06% | -2.40% | +0.71% | +0.00% | +5.24% | +13.01% | -2.13% | +25.00% | +29.55% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Chemicals: +4.0%-1.6% Q1'26: +12.9% (vs Q1'25)
-
EPS growth Chemicals: +11.7%+99.4% ★ Q1'26: +533.8% (vs Q1'25)
-
FCF margin FCF growth · Chemicals: +41.7%+0.6% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Chemicals: +7.1%+0.7% Q1'26: +0.8% (vs Q1'25)
-
ROIC Chemicals: +3.4%+0.6% Q1'26: +0.8% (vs Q1'25)
-
Share dilution Chemicals: +0.0%-1.0% ★ Q1'26: +0.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Chemicals: 0.55×3.60× ★ Q1'26: 3.12× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | A | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-14 | A | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-13 | A | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-11 | A | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-08 | A | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-07 | A | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-01 | A | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-30 | A | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-28 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 5/5 |
| 2026-04-27 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 5/5 |
| 2026-04-24 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 5/5 |
| 2026-04-23 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 5/5 |
| 2026-04-22 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 5/5 |
| 2026-04-21 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 5/5 |
| 2026-04-20 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 5/5 |
| 2026-04-17 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 5/5 |
| 2026-04-16 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 2/5 | 5/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Haruo Maruo | Chairman, Chief Executive Officer & President | — | male |
| Hidemitsu Kasahara | Executive Officer, Chief Technology Officer & GM of Research Division and Manager of R&D Section3 | — | — |
| Hideo Fukatsu | Senior MD, GM of Sales Division, Manager of Corporate Planning Division & Director | — | male |
| Hiroshi Shibata | Executive Officer & Head of 1st Research Laboratory | — | male |
| Hiroyuki Matsuda | Executive Officer, GM of Administration Division & Deputy Director of Corporate Planning Division | — | — |
| Mitsuru Takagaki | Executive Officer, Director of Sales Division 1 & Manager of Market Development Dept. | — | — |
| Shigeo Takiyama | Executive Officer, Director of Manufacturing Tech. Div. 2 & Chief Officer of R&D Dept.4 | — | — |
| Shigeru Sakaguchi | Executive Officer & Director of Technical Marketing Dept. | — | — |
| Toshiya Morishita | MD, Chief of Production Division, GM of RC Promotion Office & Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4102.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
